Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA

Blood

Volumn 98, Issue 8, 2001, Pages 2442-2447

  Reilly, Michael P ^a,b,c   Taylor, Scott M ^a,b,c   Hartman, Nealie K ^a,b,c   Arepally, Gowthami M ^a,b,c   Sachais, Bruce S ^a,b,c   Cines, Douglas B ^a,b,c   Poncz, Mortimer ^a,b,c   McKenzie, Steven E ^a,b,c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HEPARIN; MONOCLONAL ANTIBODY; THROMBIN; THROMBOCYTE FACTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHOCK; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TRANSGENIC MOUSE;

EID: 0035889119     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2442     Document Type: Article

References (34)

1. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305:208-215.
2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
3. Rock GA, Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:497-507.
4. , Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
5. Pouplard C, Amiral J, Borg J-Y, et al. Decision analysis for use of platelet-aggregation tests, carbon 14C-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111:700-706.
6. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
7. Arepaliy G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648-654.
8. Zucker MB, Katz IR. Platelet faclor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991;198:693-702.
9. Capitanio AM, Niewiarowski S, Flucinski B, et al. Interaction of platelet factor 4 wilh human platelets. Biochim Biophys Acta. 1985;89:161-173.
10. Kelton JG, Smith JW, Warkentin TE, Haywood CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
11. Horne MK III, Alkins BR. Platelel binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med. 1996; 127:435-442.
12. Newman PM, Chong NH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
13. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-930.
14. Cines DB, Kaywin P, Bina M, TomaskiA, Schreiber AD. Heparin-associated thrombocytopenia. N Engl J Med. 1980;303:788-795.
15. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
16. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196-201.
17. Visentin GP. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost. 1999;82:448-456.
18. Cassel DL, Keller MA, Surrey S, et al. Differential expression of FcγRIIA, FcγRIIB, and FcγRIIC in hematopoietic cells: analysis of transcripts. Mol Immunol. 1993;30:451-460.
19. Indik Z, Chien P, Levinson AI, Schreiber AD. Human FcγRII, in the absence of other Fcγ receptors, mediates a phagocytic signal. J Clin Invest. 1991;88:1766-1771.
20. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood. 1993;81:988-993.
21. Bauer TJ, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
22. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996; 128:367-383.
23. Pouplar C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-2536.
24. Blank M, Cines DB,Arepally G, Eldor A, Afek A, Shonefeld Y. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol. 1997;108:333-339.
25. Blank M, Eldor A, Tavor S, et al. A mouse model for heparin-induced thrombocytopenia. Semin Hematol. 1999;36(suppl 1):12-16.
26. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 (PF4) associated with heparin-induced thrombocytopenia (HIT). Blood. 1998;92:3250-3259.
27. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low affinity FcγRII genes: duplication and recombination. Science. 1990;248:732-737.
28. Kato Y, Hori S, Fujita N, Tsuruo T. A novel antiplatelet monoclonal antibody induces mouse platelet aggregation through an Fc receptor-independent mechanism. Biochem Biophys Res Commun. 1998;242:250-255.
29. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor FcγRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999; 162:4311-4318.
30. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, McKenzie SE. Thrombosis and shock induced by activating anti-platelet antibodies in human FcγRIIA transgenic mice: the interplay between antibody, spleen, and Fc receptor. Blood. 2000;96:4254-4260.
31. Zhang C, Thornton MA, Kowalska MA, Poncz M, McKenzie SE, Reilly MP. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein (PBP)/platelet factor 4 (PF4) gene locus. Blood. 2001;98:610-627.
32. Haagen IA, Geerars AJ, Clark MR, van de Winkel JGJ. Interaction of human monocyte Fcγ receptors with rate IgG2b: a new indicator for the FcγRIIA (R-H131) polymorphism. J Immunol. 1995;154:1852-1860.
33. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95:1533-1540.
34. McDonald TP, Cottrell M, Clift R. Hematologic changes and thrombopoietin production in mice after X-irradiation and platelet-specific antisera. Exp Hematol. 1977;5:291-298.